PLAINSBORO, N.J., Jan. 21, 2015 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the full market release of Integra® Reinforcement Matrix, a biological implant composed of porcine dermis that may be used for any type of tendon injury that requires surgical reconstruction. Tendon injuries are some of the most common musculoskeletal disorders, ranging from a mild ankle sprain to an Achilles tendon rupture or flexor tendon injury of the hand.
Manufactured by Stellen Medical, which has over 25 years’ experience in working with porcine dermis, the matrix has 510 (k) clearance from the Food and Drug Administration, and is made of the same material that has over 14 years of implant success in more than 40,000 surgical procedures.
“Integra is committed to providing improved clinical solutions for our upper and lower extremity surgeon customers,” said Bill Weber, Vice President, Orthopedics & Tissue Technologies. “Integra Reinforcement Matrix complements our portfolio of tendon repair products, and offers surgeons enhanced options for their patients’ needs.”
Integra Reinforcement Matrix has high tensile strength that provides durable reinforcement during the healing phase of a repaired tendon, and omni-directional suture pullout strength that minimizes tearing. The collagen matrix allows early cellular repopulation, remodeling and revascularization for long- term repair. The product is available in two convenient sizes, 4 cm X 7 cm and 5 cm X 10 cm, and is ready-to-use, hydrated, and does not require special handling before surgery.
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies, and spine hardware and orthobiologics. For more information, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading “Risk Factors” included in Item IA of Integra’s Annual Report on Form 10-K for the year ended December 31, 2013 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences: Media Gianna Sabella 609-936-2389 gianna.sabella@integralife.com Investors Angela Steinway 609-936-2268 angela.steinway@integralife.com
Help employers find you! Check out all the jobs and post your resume.
